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Defective adaptive immune responses are well studied in common variable immunodefi-
ciency (CVID) patients; however, more focus is needed on innate immune system defects
to explain CVID’s clinical and laboratory heterogeneity. This is the first study comparing
migratory function of granulocytes, oxidative burst activity of phagocytic cells, surface
integrin expressions on neutrophils and lymphocytes, natural killer (NK) cell numbers
and cytotoxic activity, natural killer T cells, lymphocyte subsets such as CD8+CD28+,
CD4+CTLA-4+ cells in CVID patients (n: 20) and healthy controls (n: 26). The relationship
between laboratory findings and some clinical was also investigated. CD3+CD8+ T
cytotoxic cells were found to be elevated in CVID patients, but CD3+CD8+CD28+ or
CD3+CD8+CD28  cells did not show any significant difference. CD4+CTLA-4+ cell per-
centages were significantly lower in CVID patients compared to healthy controls. Severe
CVID patients had decreased percentages of NK cells with increased NK cell cytotoxicity
suggesting possibly increased activation. Furthermore, CD3 CD16+CD56+CD28+ cells
of CVID patients were elevated while percentage of CD28  NK cells was decreased.
Neutrophil migration percentages were lower but and oxidative burst activity was not
affected. CD11a expressions on these cells were depressed in contrast to increased
expression of CD18. Innate immunity defects may affect the extent of recurrence and
severity of infections in CVID. Our observations highlight some of these associations and
indicate the need for further similar studies for improving better innate system evaluation
batteries for these patients. Further phenotypic correlations of these analyses will help
clinicians reach a more definitive target for the molecular genetic diagnostic of pediatric
CVID patients.
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Introduction
Common variable immunodeficiency (CVID) is a heterogeneous group of disorders characterized
by hypogammaglobulinemia, defective specific-antibody production, increased susceptibility to
infections of the respiratory and gastrointestinal tracts with encapsulated bacteria and a vari-
ety of complications such as autoimmunity, lymphoproliferation, splenomegaly, malignancy, and
granulomas (1).
Although defective adaptive immune responses with impairment of T cell and B cell maturation
and activation are common features in most CVID patients, less attention has been given to innate
immune system defects as a possible explanation for CVID heterogeneity (2).
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Neutrophils and monocytes are essential to innate immunity.
They are the first cells to migrate from the blood to the inflamma-
tory site where they kill pathogens and secrete various mediators
that regulate innate and adaptive immunity (3). Functional and
quantitative monocyte imbalances associated with T cell activa-
tion and with B cell disorders are observed in CVID (1). Mono-
cytes can exhibit chronic hyperactivity and enhanced oxidative
stress, which might contribute to autoimmune disorders, granu-
loma formation, and impaired natural killer (NK) cell-mediated
cytotoxicity (1). Patients with AIDS showed a significant reduc-
tion of phagocytosis and respiratory burst which correlated with
the number of CD4+ cells in comparison to asymptomatic HIV-
infected individuals (4). Functional steps required for the activity
of neutrophils and monocytes include migration (detected by
Migratest), recognition, adhesion, phagocytosis, and killing of the
target (detected by Phagoburst test) (3).
The role of endothelial adhesion molecules (selectins, CD62L,
superimmunoglobulin family) in the pathogenesis of CVID and
association of these molecules with the presence of splenomegaly
has been reported previously (5). Integrins CD11a/CD18 (lym-
phocyte function-associated antigen-1/LFA-1), which are found
on leukocytes help leukocyte transmigration to the inflammation
area and are involved in a broad range of immunological processes
including leukocyte extravasation, lymphocyte co-stimulatory
signaling, and T-lymphocyte alloantigen-induced proliferation.
To date, there is no study evaluating integrins on neutrophils and
lymphocytes of CVID patients.
Natural killer cells as components of the innate defense system
that targets and lyses tumor cells and virally infected cells have
been shown to be significantly reduced in CVID (6). Further-
more, in a previous study, in vitro cytotoxicity of PBMC from
CVID patients to the K562 cell line (presumed NK activity) have
been found to be normal, suggesting a compensatory mechanism
for the low numbers (7). CVID patients are prone to cancer
development, particularly lymphoma, and the deficiencies in the
functions or numbers ofNKcellsmay contribute to heterogeneous
infectious clinical findings, especially viral infections and tumor
development in some cases.
Natural killer T (NKT) cells have been implicated in both up-
regulation and down-regulation of numerous autoimmune and
inflammatory conditions, as well as tumor/immune surveillance
(8, 9). Autoimmunity and cancer are important components of
CVID and the mechanisms in their development are yet poorly
defined. Carvalho et al. (9) showed that NKT cells are circulating
at the same frequency in the peripheral blood in CVID patients
as healthy donors, but there is a skewing of NKT cell subsets in
CVID patients.
CD28 and CTLA-4 both are co-stimulatory T cell molecules,
which bind to antigen-presenting cells. CD28 transmits a stim-
ulatory signal, whereas CTLA-4 transmits an inhibitory sig-
nal to T cells. It is shown that CD28 is extremely efficient
at up-regulating IL-12-driven IFN-γ synthesis (which subse-
quently activates macrophage killing of organisms) by NK cells
and Th1 polarization. CD28-deficient NK cells were shown
to have markedly reduced ability to lyse tumor cells. CD28,
by enhancing IFN-γ synthesis, may have a profound effect on
innate immunity, Th1 development, and disease outcome (10,
11). The role of CD28-positive and CD28-deficient NK and
NKT cells in the pathogenesis of CVID has not been studied.
On the other hand, higher CTLA-4 expression, which com-
petes for binding with CD28, is responsible for increased T
cell self-reactivity. The mRNAs of CTLA-4 were reported to be
expressed at lower levels in CVID patients compared to healthy
controls (12).
In the present study, we evaluated the frequency and functional
response of innate immune cells in order to elucidate the con-
tribution of innate immunity to the pathogenesis or clinical het-
erogeneity of CVID. Clinical complications such as autoimmune
diseases, gluten enteropathy, or granulomatous lesion formation
were also compared with these parameters. Our main aim was
to generate an innate functional array for these patients, search
phenotypic associations to get clues for possible molecular genetic
diagnosis of patients.
Patients and Methods
Clinical and immunological data of 20 patients who fulfilled
criteria for CVID from the out-patient and in-patient clinics
of Ege University Faculty of Medicine, Department of Pediatric
Immunology, Izmir, Turkey were evaluated.
Patients were diagnosed and classified according to both
clinical and laboratory criteria reported by European Society
for Immunodeficiencies/Pan-American Group for Immunodefi-
ciency (ESID/PAGID) (13). Diagnosis criteria were as follows: (1)
marked decrease of IgG (at least two SDs below the mean for
age), (2) reduced serum IgA and/or IgM, (3) specific-antibody
deficiency, (4) age >2 years, and (5) exclusion of other known
causes of hypogammaglobulinemia. Ethics Committee approval
and informed written consent for participation were obtained for
all cases.
All demographic information including name, gender, date
of birth, age at onset of symptoms, age at admission, age at
diagnosis, family history and consanguinity, clinical symptoms
or complications (autoimmune disease, chronic giardiasis, gran-
ulomatosis, lymphoma or any malignancy, lymphadenomegaly,
splenomegaly, bronchiectasis, musculoskeletal system findings,
celiac-like disease), follow-up duration, and laboratory data were
recorded.
The patient group was evaluated as subgroups divided
according to published disease severity criteria for CVID
(14). Patients with splenomegaly and/or granulomatous diseases
and/or bronchiectasis and/or lower baseline IgG values (at admis-
sion lower than 270mg/dL) (n: 6) were included into the severe
disease (SD) group. Patients diagnosed as CVID but who did not
fulfill these criteria were grouped asmoderate disease (MD) group
(n: 14). As a control group, 26 healthy children (n: 26) within the
similar age range were included.
All laboratory studies performed in patient and control group
are listed in Table 1.
Whole Blood Count Assay
Whole blood count, leukocyte counts, absolute neutrophil and
lymphocyte counts, and relative ratio were performed with hemo-
counter Cell-Dyn 3700, Abbott Diagnostics, USA.
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TABLE 1 | Flow cytometric analyses performed in patient and control
groups.
Innate immunity
Migration, phagocytosis, oxidative burst
Migratest (chemotaxis of granulocytes)flow cytometry
Phagoburst testflow cytometry
Integrins (adhesion molecules)
CD11a+ lymphocytes
CD11a+ neutrophils
CD18+ lymphocytes
CD18+ neutrophils
Natural killer cells
CD3 CD16+CD56+ (NK cell)
Natural killer cell cytotoxicityflow cytometry
CD3 CD16+CD56+28+
CD3 CD16+CD56+28 
Natural killer T cells
CD3+CD16+CD56+ (NKT cell)
CD3+CD16+CD56+28+
CD3+CD16+CD56+28 
CTLA-4+ cells
CD3+CD4+CTLA-4+
Serum Immunoglobulin Assay
Serum immunoglobulins (IgG, IgA, IgM) were analyzed quanti-
tatively by Dade Behring BNII nephelometer, Siemens, Germany
and compared with age related normal levels (15).
Flow Cytometric Analysis
All flow cytometric analyses were made using FacsCalibur and
all cell subpopulations were acquired using CellQuest Pro soft-
ware (BD Biosciences, USA) and Flow-Jo software version 8.8.9
(Treestar, USA).
The flow cytometric data in the text were given according to
standardized publishing rules (16–18).
Lymphocyte Subsets Assay
Percentages and absolute counts of lymphocyte subsets (CD3+,
CD19+, CD3+CD4+, CD3+CD8+, CD3+HLA DR+,
CD3 CD16+CD56+, CD3+CD16+CD56+) were investigated
by flow cytometry, FACSCalibur, Becton Dickinson (BD),
USA. CD3/CD4/CD8/CD45, CD3/CD19/CD16/56/CD45, and
CD3/HLA-DR multicolor antibody reagents were used for
staining. Lymphocytes were gated based on their forward and
side scatters and all cell subpopulations were acquired using Cell
Quest-Pro software (BD Biosciences).
CTLA-4 Intracellular Expressions on CD3+CD4+
Lymphocytes
Heparinized whole blood (100 µL) was stained with anti-CD3
and anti-CD4monoclonal antibodies (moAb) (BectonDickinson,
USA). Erythrocytes were incubated with 2mL of lysing solution
(Becton Dickinson) for 10min. After washing with phosphate-
buffered saline containing 0.1% bovine serum albumin (PBS-
BSA), leukocytes were suspended in FACS permeabilizing solu-
tion (Becton Dickinson) for 10min. The cells were stained with
phycoerythrin (PE)-conjugated anti-CD152 (CTLA-4) moAb for
30min, rinsed, and resuspended in PBS-BSA. The number of cells
that were positive for intracellular CD4+ CTLA-4+ was expressed
as a percentage ofCD3+ gated cells using Flow-Jo software version
8.8.9 (Treestar, USA) (19, 20).
CD28 Surface Expressions on CD3 CD16+CD56+
(NK), CD3+CD16+CD56 (NKT), and CD3+CD8+
(T Cytotoxic) Cells
Percentages of CD3 CD16+CD56+CD28+, CD3+CD16+CD56
CD28+, CD3+CD8+CD28+, CD3+CD8+CD28  subpopula-
tions were analyzed according to cell surface staining instructions
using anti-CD3 APC, anti-CD8 PE, anti-CD16 PE, anti-CD56 PE,
and anti-CD28 FITC moAb (Becton Dickinson, USA) in hep-
arinized blood samples. CD28 percentages on gated NK and NKT
cells were analyzed with Flow-Jo software version 8.8.9 (Treestar,
USA). T cytotoxic cells were given as CD8+CD28+ percentages
on CD3+ gated cells.
CD11a and CD18 Surface Expressions on
Neutrophil Granulocytes and Lymphocytes
Surface expressions of CD11a and CD18 on lymphocytes and
neutrophil granulocytes were analyzed according to cell surface
staining instructions using anti-CD11a FITC and anti-CD18 PE
moAb (Becton Dickinson, USA) in heparinized blood samples.
Gating strategy for defining the integrins was as follows: lym-
phocytes and neutrophils were gated based on their forward
and side scatters. Compensations were made if needed and the
percentages of the integrins were assessed using Cell Quest-Pro
software.
Oxidative Burst Activity of Monocytes and
Granulocytes (Phagoburst Test)
The quantification of the oxidative burst activity of mono-
cytes and granulocytes in heparinized whole blood was deter-
mined by Phagoburst test, Orpegen Pharma, Heidelberg, Ger-
many. The test determines the percentage of phagocytic cells,
which produce reactive oxidants in the presence of stimulants
as Escherichia coli (E. coli), fMLP (n-formyl-methionine-leucine-
phenylalanine), and PMA (phorbol-12-myristate-13-acetate) and
cells’ enzymatic activity. The kit has been validated using an
independent assay in preliminary studies and the results were
similar (Normal reference values are as follows: for monocytes by
stimulant E. coli: 70–100%; for granulocytes by stimulant E. coli:
95–100%, fMLP: 1–20%, and PMA: 99–100%).
Chemotactic Functionof Granulocytes(Migratest)
Chemotactic function of neutrophilic granulocytes was evalu-
ated by Migratest, Orpegen Pharma, Heidelberg, Germany. The
test allows determination of the number of neutrophils, which
have migrated through cell culture inserts toward a concentration
gradient of the chemoattractant fMLP. More than 95% activated
granulocytes were accepted as normal.
Cytotoxic Activity of NK Cells
Quantification of the cytotoxic activity of NK cells was made
according to NK test instructions, Orpegen Pharma, Heidelberg,
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Germany. K562 (chronic myeloid leukemic cell line) target cells
were cultured and labeled with a lipophilic green fluorescent
membrane dye, DIOC18 (3) (3,30-dioctadecyloxa carbocyanine
perchlorate), Life Technologies, USA, and then incubated with
effector mononuclear cells, which were obtained from fresh hep-
arinized blood by density gradient centrifugation on Biocoll
(Biochrom GmbH) separating solution. The percentages of target
cells killed by effector cells and live cells were determined. The
percent specific cytotoxicity of mononuclear cells (presumed NK
activity) is determined by subtracting the percentage of dead
cells in the incubated targets alone (target negative control tube)
from the percentage of killed target cells in the test samples (test
tube). Normal reference percent specific toxicity differs according
to target/effector cell ratio. All assays were performed in 1:25
target/effector cell ratio and a tube with 1:25 target/effector cell
ratio including interleukin-2 was used as positive control tube.
All cell subpopulations were measured by flow cytometry and
analyzed with CellQuest Pro software (BD Biosciences).
Specific-Antibody Response
Specific-antibody responses to tetanus andHaemophilus influenza
antigens were analyzed by commercial ELISA kits and were previ-
ously recorded.
Evaluation of Autoimmunity
Antinuclear antibody (ANA) positivity in serum was determined
by immunoflorescence (IF) on mosaic Hep-20-10/liver monkey
cell slides (Euroimmun, Lübeck, Germany) in a double-blind set-
ting, in order to evaluate autoimmunity in patients. ANA IF titers
of 1:100 were taken as cut-off titers. Anti-neutrophil cytoplasmic
antibody (ANCA) positivity with a 1:16 cut-off titer was also
evaluated by IF. Titrimetric qualitative determinations () were
used. All autoimmune diseases (autoimmune hemolytic anemia,
autoimmune thrombocytopenia, rheumatoid arthritis, pernicious
anemia) records were also evaluated.
Evaluation of Celiac-Like Disease Findings
Gluten enteropathy was evaluated by patients’ data records for
anti-gliadin (AGA) and anti-tissue transglutaminase (TTG) IgA
antibodies levels, which were performed with ELISA.
Statistics
All clinical and laboratory data were evaluated in relation with
each other and compared in different patient profiles and con-
trol groups. Statistical analyses were performed by using SPSS
Windows Version 17.0, SPSS Inc., Chicago, IL, USA. Data were
expressed as mean plus or minus SD except when indicated other-
wise. Correlation comparisons between paired samplesweremade
by Pearson’s product moment correlation coefficient. Statistical
comparisons of numeric data were made using Student’s t-test
and classified data were evaluated by chi-square test. A two-sided
p-value <0.05 was considered to indicate statistical significance.
Results
A total of 20 CVID patients (n= 3 female, 15% and n= 17 male,
85%) with a mean age of 173.2 77.9months and 26 healthy
controls (n= 12 female, 46% and n= 14 male, 54%) with a mean
age of 133.09 63.0months were included in this study.
All demographic and clinical characteristics of the patient
group are summarized in Table 2. According to disease severity
criteria, 30% of patients (n= 6) had severe and 70% of patients
(n= 14) had MD. In whole patient group, the mean age at the
onset of symptoms was 70.0 60.8 and 93.7 58.7months at
diagnosis. A total of 17% of the patients (n= 3) were born to con-
sanguineous parents. Consanguinity had a significant relation-
ship with disease severity (p: 0.052). Family history for primary
immune deficiencies was positive in five patients (25%). Infection
was the most common cause of admission for 18 patients. The
other reasons for admission were autoimmune hemolytic anemia
and severe lymphadenomegaly. The most frequent infection types
were sinopulmonary tract infections and gastroenteritis. Specific-
antibody response was negative in six patients (30%). All patients
were followed up for 80.6 70.3months. IVIg replacement ther-
apy was started at the mean age of 83 51.1months and the mean
duration for IVIg replacement was 111.5 59.9months. Neither
the mean age of starting IVIg therapy (p: 0.200) nor IVIg duration
(p: 0.394) showed statistical significance in relation to disease
severity.
Major complications in the patient group, observed dur-
ing follow-up were as follows: bronchiectasis (n= 4, 20%),
splenomegaly (n= 5, 25%), osteoporosis (n= 6, 30%), delayed
growth (n= 6, 30%), autoimmunity (n= 5, 25%), hepatic enlarge-
ment (n= 4, 20%), gluten-like enteropathy (n= 2, 10%), gran-
uloma formation (n= 4, 20%), and lymphoma (n= 2, 10%).
Failure to thrive, autoimmunity, gluten-like enteropathy, osteo-
porosis, bronchiectasis, splenomegaly, and hepatomegaly were the
significantly increased complications in SD group. The disease
severity showed no significant correlation with granuloma forma-
tion (p: 0.243), lymphoma evolution (p: 0.360), or autoimmunity
(p: 0.360).
Autoimmune clinical findings were observed in five patients;
chronic arthritis (n= 1), inflammatory bowel disease (n= 2),
TABLE 2 | Patient group characteristics (meanSD) (*p<0.05, independent t-test).
All patients
(n: 20)
Moderate
disease (n: 6)
Severe
disease (n: 14)
p Male (n: 17) Female (n: 3) p
Age at the time of study (months) 173.2 77.9 163.2 63.1 199.4 112.6 0.394 184.2 76.1 118.6 75.6 0.192
Age at onset of symptoms (months) 70.0 60.8 58.3 55.7 108 69.2 0.257 71 62.1 65.6 67 0.908
Age at diagnosis (months) 93.7 58.7 84.6 58.3 123 57.4 0.297 96.2 61.2 81.6 53.8 0.709
Follow-up duration (months) 80.6 70.3 79.3 67.5 84.7 89.9 0.899 92.7 71.9 24 10.4 0.004*
IVIg treatment duration (months) 111.5 59.9 94.7 43.2 178.5 89.8 0.404 111.5 59.9
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relapsing polychondritis (n= 1), autoimmune hemolytic anemia
(n= 1), and thrombocytopenia (n= 2), spondylarthropathy of the
hip (n= 1), sacroileitis (n= 1), and vasculitis (n= 1).
General laboratory data of study group are summarized in
Table 3. At the time of diagnosis, white blood cell (WBC) and
absolute lymphocyte counts did not show any significant differ-
ence between disease and control groups.
Immunoglobulins
Baseline IgG, IgM, and IgA levels in the patient group were
405.8 181.6, 46.3 41.6, and 43.4 60.3mg/dL, respectively,
before commencement of IVIg therapy. There was a significant
difference between severe and MD groups (p: 0.010) for IgG
concentrations, which were lower in severe group (Table 3).
Lymphocyte Subsets
Percentages of CD19+ B cells were lower in the patient group
compared to controls (p: 0.004). The decrease was more signif-
icant in the SD group (Table 3), but there was no significant
difference correlating to disease severity. A statistically significant
difference between the two groups for CD3+ T cells (p: 0.039)
was relative to decrease in CD19+ B cells. CD3+CD8+ T cyto-
toxic cells and HLA-DR+ active T cells were higher in the SD
group than the MD group and there was also a significant differ-
ence between patient and control groups, respectively (p: 0.007,
p: 0.009). CD3+CD8+CD28+ (p: 0.732) or CD3+CD8+CD28 
cells (p: 0.634) (Table 3).
CTLA-4 Cells
CD4+CTLA-4+ cell percentages on CD3+ lymphocytes were
0.47 0.47 and 1.36 1.50 in disease and control groups and
there was significant difference between both groups (p: 0.016).
In the SD group, it was higher (0.68 0.61) than in theMD group
(0.39 0.42), but the difference here was not significant (p: 0.319).
NK Cells and NK Cell Subsets
Percentages of CD3 CD16+CD56+ natural killer cells of patient
and control groups did not show any statistically significant differ-
ence (p: 0.107), but it was significantly lower in the SD group than
in the moderate group (p: 0.012). On the CD3 CD16+CD56+
cells, the percentages of CD28 positivity were higher (p: 0.008) and
CD28 negativity were lower in the patient group than the control
group (p: 0.006) (Table 4). Ratio ofNK cells (p: 0.401), CD28+NK
(p: 0.915), or CD28 NK (p: 0.944) cells did not effect the presence
of lymphoma.
NK Cell Cytotoxicity
Effector cells, which were collected from PBMC of CVID patients
and healthy controls, were incubated with DIOC dyed K562 target
cells and then live and dead cell groups were determined using
flow cytometry. Increased percentages of dead target cells in pos-
itive control tubes in comparison with negative control and test
tubes showed us that the test was trustworthy. The percentage of
dead target K562 cell was significantly higher in the patient group
than the control group (p< 0.0001). SD group patients had higher
dead cell percentages than MD group, but the difference was not
statistically significant (p: 0.075).
In vitro cytotoxicity of PBMC (presumed NK activity) from
CVID patients to the target K562 cell line was determined by
subtracting the percentage of dead cells in the incubated targets
alone (target negative control tube) from the percentage of killed
target cells in the test samples (test tube). The percentage of NK
cell specific toxicity has been found to be higher in the patient
group than the control group (p: 0.002) but the difference was not
statistically significant between moderate and SD groups (0.873)
(Table 5) (Figure 1).
NKT Cells
CD3+CD16+CD56+ cell percentages did not show any difference
between patient and control groups (p: 0.288) or between severe
and moderate groups (p: 0.077). Neither CD28+ nor CD28  cell
percentages on NKT cells showed difference between the two
groups (Table 6). NKT cells (p: 0.256), CD28+ NKT (p: 0.592),
or CD28  NKT (p: 0.268) cells did not show any difference in the
presence of lymphoma or autoimmunity.
Migration
Four patients in the disease and one patient in the control group
showed decreased migration capacity if more than 95% activated
granulocytes were accepted as normal when the number of neu-
trophils that have migrated through cell culture inserts toward a
concentration gradient of the chemoattractant fMLP were deter-
mined. Percentage of activated granulocytes was 93.7 5.08 and
97.7 4.98 in disease and control groups, respectively (p: 0.025)
(Table 7).
Phagocytosis
Percentages of phagocytic granulocytes, which produce reactive
oxidants in the presence of stimulants as fmLP, PMA, and E. coli
were 6.55 5.48, 94.9 7.86, and 91.8 13.7 in patients and
6.95 6.54, 98.1 3.19, and 95.5 4.43 in the control group,
respectively. Oxidative burst activity was found to be decreased
in six patients (30%); however, the groups did not show any
significant difference (Table 7).
CD11a+ and CD18+ Cells
Integrin CD11a percentages on lymphocytes and neutrophils
showed significant difference between patient and control groups
(p: 0.042, p: 0.024, respectively) while CD18 percentages did not
differ in either group (p: 0.346, p: 0.935), but mean florescence
intensity (MFI) of CD18 on both neutrophils and lymphocytes
was significantly increased in the patient group (p: 0.012 and
p: 0.035, respectively) (Table 8) (Figure 2).
Discussion
Common variable immunodeficiency is a highly heterogeneous
immunodeficiency syndrome and about 20% of CVID patients
have a family history of immune deficiency and parental consan-
guinity. In our study, mean age at the beginning of symptoms
was about 7 years and mean age at diagnosis was about 8 years
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TABLE 3 | Laboratory data of CVID patient and control groups (p1: between moderate and severe disease groups; p2: between patient and control groups)
(*p< 0.05).
Patient group (meanSD) Control group
(meanSD)
p2
All patients
(n: 20)
Moderate
disease
Severe
disease
p1
Leukocyte count (103/µL) 7.47 4.39 7.52 4.94 7.27 1.83 0.922 7.21 2.28 0.817
Absolute lymphocyte cells/mm3 2642.7 1542.1 2686.6 1690.9 2488.8 1023.1 0.829 2728.1 1024.0 0.840
Initial IgG (mg/dL) 405.8 181.6 461.7 162.3 210.2 85.1 0.010* – –
Initial IgA (mg/dL) 43.4 60.3 35.7 45.6 68.4 100 0.361 – –
Initial IgM (mg/dL) 46.3 41.6 54.3 44.1 18.1 4.38 0.129 – –
CD19+ B cells % 7.62 6.47 8.92 7.27 4.60 2.41 0.179 13 5.53 0.004*
cells/mm3 260.8 393.2 289.5 437.3 160.2 173.7 0.578 372.6 215.7 0.269
CD3+ T cells % 78 11.2 74.3 10.8 86.6 6.46 0.019* 71.7 8.90 0.039*
cells/mm3 1890.2 1177.1 1688 1012.6 2598.2 1596.6 0.180 1875.3 747.9 0.963
CD3+4+ T helper cells % 37.4 12.6 37.8 13.2 36.5 12.1 0.831 39.7 9.12 0.476
cells/mm3 914.1 651.3 843.5 534.4 1161.2 1030.4 0.406 1012.8 426.1 0.574
CD3+CD8+ T cytotoxic cells % 35.6 13 31.9 9.80 44.2 16.5 0.052* 26.2 6.28 0.007*
cells/mm3 840.4 610.5 756 578.9 1135.7 714.3 0.286 683.9 268.4 0.324
CD3+CD8+CD28+ % 22.2 8.19 22.1 8.38 22.4 8.53 0.952 23 6.18 0.732
cells/mm3 0 0 0 0 0 0 – 149.3 52.9 0.313
CD3+CD8+CD28  % 16.1 11.6 14.9 9.22 18.7 16.4 0.523 15.1 7.60 0.634
cells/mm3 0 0 0 0 0 0 – 102.8 79.2 0.112
CD3+HLA-DR+ Active T cells % 17.9 18 13.2 11.6 28.7 26.1 0.216 6.18 3.11 0.009*
cells/mm3 378.8 615.3 215.5 253 950.2 1143.9 0.290 107.7 74.5 0.080
CD4+CTLA-4+ cells on CD3+ % 0.47 0.47 0.39 0.42 0.68 0.61 0.319 1.36 1.50 0.016
cells/mm3 7.78 8.60 6.82 6.76 11.3 15.1 0.661 26.3 35.2 0.065
TABLE 4 | Natural killer cells (NK cell) in CVID patient and control groups (p1: between moderate and severe disease groups; p2: between patient and
control groups) (*p< 0.05).
Patient group (meanSD) Control group
(meanSD)
p2
All patients Moderate disease Severe disease p1
CD3 CD16+CD56+ % 20.5 18.9 25.6 20.4 8.83 5.69 0.012* 26.2 11.6 0.107
cells/mm3 103.7 154.8 126.5 169.5 23.8 18.2 0.253 232.4 256.7 0.073
CD3 CD16+CD56+28+ % 20.0 30.3 17.4 29.6 26.2 33.8 0.570 0.17 0.27 0.008*
cells/mm3 22.6 62 25.2 70.2 13.5 18.2 0.752 0.39 0.59 0.147
CD3 CD16+CD56+28  % 78.3 31.1 81.6 30.7 70.8 33.7 0.492 99.8 0.26 0.006*
cells/mm3 80.1 148.29 100.3 163.6 9.45 3.740 0.293 232.0 256.2 0.034*
TABLE 5 | The mean percentage of target K562 cells killed by effector NK cells (at 1:25 target/effector cell ratio) and NK cell specific toxicity in patient and
control groups (p1: between moderate and severe disease groups; p2: between patient and control groups) (*p< 0.05).
Patient group (meanSD) (n= 11) Control group
(meanSD)
(n= 14)
p2
All patients Moderate disease Severe disease p1
Target dead cells% Test tube (1:25) 34.1 11.4 30.4 9.7 44.0 10.9 0.075 10.8 14.6 0.000*
Positive control tube (1:25-IL2) 35.7 11.7 32.4 10.2 44.6 12.7 0.129 11.8 15.5 0.000*
Negative control tube 8.16 16.0 4.1 3.91 18.8 31.5 0.189 5.71 12.9 0.676
NK cell specific toxicity% 26.9 13.3 27.3 11.6 25.8 27.3 0.873 8.2810.6 0.002*
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FIGURE 1 | NK cell specific toxicity assay, comparison of patients with controls (p=0.002).
and parental consanguinity was 17%. Consanguinity had sig-
nificant relationship with disease severity. Although diagnostic
delay was not long (about 1 year), 20% of patients presented with
bronchiectasis and 30% with osteoporosis and growth failure.
SomeCVIDpatientsmay present lowperipheral B cell numbers
associated with defective terminal B cell maturation. Wehr et al.
reported that most of their CVID patients had low B cell counts
(21). Similar to our previous study (22), there was no significant
difference between severe and moderate patient groups in terms
of B cell numbers; however, B cells in total CVID patients were
significantly lower than in healthy controls (Table 3). CD3+CD8+
T cytotoxic cells and HLA-DR+ active T cells were higher in
SD group than MD group and there was a significant differ-
ence between patient and control groups (p: 0.007, p: 0.009,
respectively).
In a study conducted by North et al. (23), in CVID patients,
there was a significant increase in the mean proportion of
CD3+CD8+CD28  cells compared with normal donors, but
normal proportions of HLA DR+CD8+ cells. The authors also
reported a failure of activation and IFN-γ production in the sup-
pressor CD28  population and concluded that this phenotypic
and functional shift in the CD8+ cells may lead to the failure
of CD4+ T cells to respond to antigen and be causing the anti-
body deficiency seen in this disease (23). In contrast to these
findings, in our study, CD3+CD8+CD28+ (cytotoxic) (p: 0.732)
or CD3+CD8+CD28  (suppressor) cells (p: 0.634) did not had
any statistically significant difference between the two groups
(Table 3).
Autoimmune disorders occur with a higher incidence in CVID
patients than in the general population. Approximately 20–30% of
CVIDpatients develop autoimmune disorders, sometimes present
as the first manifestation of the disease (24). Juvenile idiopathic
arthritis (JIA), pernicious anemia, autoimmune tiroiditis, alope-
cia areata, primary biliary cirrhosis, vitiligo, and systemic lupus
erythematosus have been described in CVID; however, the most
common types reported are idiopathic thrombocytopenic pur-
pura (ITP) and autoimmune hemolytic anemia (AIHA) (24).
AIHA (4/14, 28.5% of total autoimmune diseases observed in the
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TABLE 6 | Natural killer T cells (NKT cell) in CVID patient and control groups (p1: between moderate and severe disease groups; p2: between patient and
control groups) (*p< 0.05).
Patient group (mean+SD) Control group
(mean+SD)
p2
All patients Moderate disease Severe disease p1
CD3+CD16+CD56+ % 0.57 0.49 0.70 0.49 0.27 0.37 0.077 1.51 3.85 0.288
cells/mm3 0 0 0 0 0 0 – 19.5 24.4 –
CD3+CD16+CD56+28+ % 15.6 19.0 18.7 20.6 8.55 13.4 0.287 19.0 17.5 0.544
cells/mm3 0 0 0 0 0 0 – 2.53 3.01 –
CD3+CD16+CD56+28  % 67.3 3.80 63.4 32.1 76.4 31.9 0.417 78.6 17.5 0.164
cells/mm3 0 0 0 0 0 0 – 16.6 23.3 –
TABLE 7 |Migration and oxidative burst activity in CVID patient and control groups (p1: between moderate and severe disease groups; p2: between patient
and control groups) (*p< 0.05).
Patient group (meanSD) Control group
(meanSD)
p2
All patients Moderate disease Severe disease p1
Migratest (% activated granulocytes) 93.7 5.08 92.5 5.55 96.4 2.23 0.037* 97.7 4.98 0.025*
Oxidative burst (% phagocytic cells
which produce reactive oxidants)
fMLP 6.55 5.48 6.11 5.53 7.57 5.72 0.600 6.95 6.54 0.836
PMA 94.9 7.86 94.5 9.34 95.9 2.57 0.728 98.1 3.19 0.109
E. coli 91.8 13.7 90.7 15.8 94.1 7.33 0.625 95.5 4.43 0.257
TABLE 8 | Integrins (adhesion molecules) in CVID patient and control groups (p1: between moderate and severe disease groups; p2: between patient and
control groups) (*p< 0.05).
Patient group (meanSD) Control group
(meanSD)
p2
All patients Moderate disease Severe disease p1
CD11a+ lymphocytes % 91.6 10.2 89.7 11.8 95.7 3.18 0.249 96.6 5.30 0.042*
cells/mm3 2227.7 1352.3 2018.8 1177.7 2906.5 1844.4 0.264 2549.5 1031.4 0.418
CD11a+ neutrophils % 78.4 29.5 78.5 32.6 78.3 23.2 0.988 95.1 9.52 0.024*
CD18+ lymphocytes % 96.6 6.28 96.2 7.58 97.5 1.68 0.691 98.3 5.45 0.346
cells/mm3 2428.1 1534 2241 1410.1 3036.2 1987.8 0.382 2643.4 1073.4 0.626
MFI 401.9 112.4 382.9 90.0 446.3 153.6 0.564 323.5 106.6 0.035
CD18+ neutrophils % 99.6 0.59 99.8 0.04 99.2 1.0 0.196 99.7 0.55 0.935
MFI 1010.5 597.8 865 448.1 1349.8 798.9 0.322 657.2 401.4 0.012
study), JIA (4/14, 28.5%), and ITP (3/14, 21.4%) were the most
common autoimmune disorders in Abolhassani et al.’s study (24).
In our study, autoimmune diseases were observed in five cases
(25%) and four of them were in the SD group.
CTLA-4 is a co-stimulatory molecule, which transmits
inhibitory signals to T cells. In our previous study (22), we have
reported that carrying G allele or GG or AG genotypes increases
the risk of developing CVID approximately twofold. Intracellular
CTLA-4 expressions were examined by flow cytometry in this
study. CD4+CTLA-4+ percentages on CD3+ lymphocytes were
0.47 0.47 and 1.36 1.50 in disease and control groups and
there was significant decrease in CVID patients. Ueda et al.
(25) have reported that certain common autoimmune diseases
are caused in part by inherited changes in CTLA-4 expression
that presumably increase T cell self-reactivity. Schubert et al.
(26) identified nonsense, splice site, and missense mutations in
CTLA-4 genes in 14 patients from six families. These patients
presented with a complex immune dysregulation syndrome
characterized by hypogammaglobulinemia, recurrent infections,
and multiple autoimmune clinical features diagnosed as CVID
(26). However, in our study, CTLA-4 expressions in our five
CVID cases with autoimmunity did not show any significant
difference from other CVID cases and healthy donors (data not
shown).
Trujillo et al. (2) found amarked, though not significant, reduc-
tion in absolute numbers ofNK cells inCVIDpatients. Circulating
NK cell numbers are clearly depleted in CVID patients in most of
the studies; this appears to have no short-term clinical relevance,
since the patients are not prone to herpes viruses, as has been
reported in some patients with isolated NK cell deficiencies (6).
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FIGURE 2 | CD18 surface expression (MFI) on leukocytes of CVID
patients compared with controls (p< 0.05).
In our study, severe CVID patients had significantly lower per-
centages of NK cells compared to moderate patients. However, no
significant difference was found between all patients and healthy
controls (Table 4). NK cell deficiency in severe CVID cases might
amplify the defective functioning of other compartments of the
immune system, further compromising tumor surveillance and
protection against viral infection (1).
CD28, the major co-stimulatory ligand for CD80/86, has been
reported to be present on the surface of human NK cells (27).
CD28 costimulation has been shown to induce optimal prolif-
eration of murine NK cells and enhance IFN-γ secretion, and
the CD28 pathway has been shown to be involved in cytotoxic
killing of tumor cells (10). In addition, CD28-deficient NK cells
were shown to have markedly reduced ability to lyse syngeneic
tumor cells (10). However, some other studies have raised doubts
on the expression of CD28 by human NK cells using a series of
mAbs recognizing CD28 only on T cells (10). Therefore, the role
of the CD28 co-stimulatory pathway in influencing the nature
of NK cell responses remains controversial. In our study, on
CD3 CD16+CD56+ NK cells of CVID patients, the percentages
of thosewithCD28+ were significantly higher (p: 0.008) than con-
trols while CD28  NK cells were significantly decreased in CVID
cases (p: 0.006) (Table 4). This finding may be related to a com-
pensatory mechanism for protection against viral infections and
also for prevention of developing tumors such as lymphoma. We
had only two CVID cases with lymphoma and we could not find
any relationship between lymphoma formation and percentage of
CD28-deficient NK cells.
Natural killer cell-mediated cytotoxicity is believed to play
an important role in immune surveillance against cancer (28).
The possible role of NK cell-mediated immunity and the devel-
opment of malignant disease in humans is one of the popular
fields of investigation in recent years. It is still not clear whether
CVID patients with or without lymphoma present depressed or
increased NK cytotoxicity. Orange et al. (29) evaluated three
patients with NEMO (NF-κB essential modifier) mutations and
HED-ID (hypohidrotic ectodermal dysplasia with immune defi-
ciency). These patients had normal percentages of peripheral
blood NK cells, but impaired NK cell cytotoxic activity. The
authors reported that NEMO participates in signaling pathways
leading to NK cell cytotoxicity and that IL-2 can activate NF-κB
and partially overcome the NK cell defect in patients with NEMO
mutation (29). On the other hand, Liu et al. (30) identified a novel
NF-κB2mutation in early-onset CVID and reported that NF-κB2
gene mutations are one of the causative agents for this hetero-
geneous disease (29). In our study, CVID patients had strikingly
increased NK cell cytoxicity, CD28+ NK cell ratio in comparison
with healthy controls. Thismay be the result of repeated activation
in patients due to recurrent infections and autoimmunity, showing
enhanced lytic activity, thus suggesting an intact NK cell function
in CVID patients.
Because of the important interactions of B cells with NKT
cells, we measured their frequencies in CVID patients and com-
pared them with healthy controls. CVID represents a spectrum
of diseases, and different genetic causes might lead to differences
in NKT cell expression. There are very limited results to assess
NKT cell frequency in CVID patients. In Carvalho’s study with
CVID patients, CD4+NKT cells were at higher frequencies and
CD8+NKT cells were at lower frequencies (9). In the same study,
higher percentages ofNKTcells expressedCCR5 inCVIDpatients
when compared with healthy controls. In a study by Trujillo et al.
(2), CD1d-restricted TCR invariant natural killer cells (iNKT)
cells were significantly decreased in the peripheral blood of most
of the CVID patients. In our study, CD3+CD16+CD56+ cell per-
centages did not show any difference between patient and control
groups or between severe and moderate groups. Neither CD28+
nor CD28  cell percentages on NKT cells showed difference
between the two groups (Table 6). Further studies are needed to
clarifywhether altered absolute numbers or functions ofNKTcells
in CVID patients could play a role for the impaired B cell function.
Blood monocyte and neutrophil leukocyte phagocytic func-
tions can be evaluated by chemotaxis, phagocytosis, and super-
oxide anion production. We addressed whether CVID is asso-
ciated with abnormalities in polymorphonuclear neutrophils as
they constitute an important compartment of innate immunity
and play a key role in host defense against invading microor-
ganisms. We used flow cytometry to examine PMN functional
abnormalities in CVID patients, using whole blood. Four CVID
patients and one in the control group showed decreasedmigration
capacity. Percentage of migrated granulocytes was significantly
decreased in CVID patients compared to controls (Table 7).
In addition, oxidative burst activity was found to be decreased
in six patients (30%), but no significant difference was found
between disease and control groups regarding oxidative burst
activity. Amoras et al. (31) evaluated these functions in 9 CVID,
8 XLA (X-linked agammaglobulinemia), and 17 normal subjects.
Phagocytosis was found to be significantly decreased in CVID
and XLA patients and chemotaxis of monocytes was reduced in
XLA patients. Superoxide anion production, however, did not
differ between CVID, XLA, and the control groups (31). Casulli
et al. (32) demonstrated that PMN from CVID patients exhibited
a decrease in degranulation, phagocytosis, and reactive oxygen
species production. Badolato (33) explained themechanismof this
aberration and reported that lower levels of CXCR5 and CCR7 are
associated with reduced migration of these cells to CXCL13 and
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CCL21/CCL19, respectively, thereby preventing their homing. It
is proposed that impaired chemotaxis and phagocytosis of phago-
cytic cells may be characteristics of the innate immune system in
CVID patients, providing a new direction for the pathogenesis
of this immunodeficiency. However, our current results did not
confirm this comment.
It is very important for lymphocytes to home to lymph nodes.
Upon cell activation, L-selectin is rapidly shed and a tighter
adhesion between leukocytes and endothelial cells is mediated by
integrins (e.g., lymphocyte function-association antigen-1, LFA-1;
CD11a, CD18) (5). Since adhesionmolecules are important in var-
ious inflammatory and immunological responses, we wanted to
examine whether CVID patients showed any disturbances in the
expression of CD11a and CD18 on lymphocytes and neutrophils.
CD11a percentages on lymphocytes and neutrophils showed
significant decrease in patients in relation to control groups.
CD18 percentages did not differ between groups but CD18 MFI
was significantly increased in patients suggesting an activated
stage of leukocytes (Table 8) (Figure 2). The changes we have
observed in these adhesion molecules may have clinical impli-
cations in CVID. In our study, decreased neutrophilic CD11a
expression was associated with the presence of celiac-like disease
and bronchiectasis. The altered expression of these molecules
on leukocyte subsets may possibly influence the interactions
between these cells, which may impair the immune response of
patients.
This is the first study examining migratory function of gran-
ulocytes, oxidative burst activity of phagocytic cells, surface
integrin expressions on neutrophils and lymphocytes, NK cell
numbers and cytotoxic activity, NKT cell numbers, and lym-
phocyte subsets such as CD8+CD28+, CD4+CTLA-4+ cells
in the same CVID patient group. As a result, CD3+CD8+ T
cytotoxic cells were found to be elevated in CVID patients, but
CD3+CD8+CD28+ or CD3+CD8+CD28  cells did not show
any difference. Severe CVID patients had decreased percent-
ages of NK cells and increased NK cell cytotoxicity, suggesting
repeated activation of this system due to infections. Furthermore,
CD3 CD16+CD56+CD28+ cells of CVIDpatientswere elevated
while percentage of CD28  NK cells was decreased. Neutrophil
migration percentages were lower but oxidative burst activity was
not affected in the patient group. CD18 expression on leukocytes
was increased suggesting an activated stage. CD11a expressions on
these cells were depressed.
One of the limitations of our study is the small number of
patients divided in relation to their clinical characteristics, which
may reduce the power of statistical analyses performed. Another
limitation is the fact that all of our patients receive IVIg periodi-
cally. Although some of the values did not differ between patient
and healthy controls, it would be best to have the opportunity to
test these patients before treatment, also. As reported in previous
studies, IVIgs modulate the ability of the innate immunity to trig-
ger T cell activation, influence NK cell-dependent tumor surveil-
lance by protein–glycan interactions and modulate expression of
adhesion molecule on cell surfaces (34–36).
Generation and routine use of a functional innate test sys-
tem will help clinicians better correlate clinical phenotypes and
provide more accurate molecular diagnostic approach for CVID
patients.
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